Biosimilars in Inflammatory Bowel Disease: Angels or Demons?
نویسندگان
چکیده
منابع مشابه
Biosimilars in Inflammatory Bowel Disease: Angels or Demons?
Submit Manuscript | http://medcraveonline.com related cost has increased consistently [3]. At the moment, there are six biological agents licensed by FDA for the treatment of CD (infliximab, adalimumab, golimumab, certolizumab, vedolizumab, and natalizumab, the last two being an anti-α4β7 and anti-α4β1integrin, respectively), and three for UC (infliximab, adalimumab, and vedolizumab), whereas t...
متن کاملMesenchymal Stem Cells: Angels or Demons?
Mesenchymal stem cells (MSCs) have been used in cell-based therapy in various disease conditions such as graft-versus-host and heart diseases, osteogenesis imperfecta, and spinal cord injuries, and the results have been encouraging. However, as MSC therapy gains popularity among practitioners and researchers, there have been reports on the adverse effects of MSCs especially in the context of tu...
متن کاملChallenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
In this article we discuss the challenges of delivering a high quality Transition care. A good understanding of the adolescent needs with good communication between Transition care physicians and the patient is essential for good continuity of care. Despite availability of several guidelines, one model doesn't fit all and any transition service development should be determined by the local need...
متن کاملUse of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the management of inflammatory bowel disease in those cases which are refractory to conventional treatment; however these drugs are not risk-free and their use has substantially increased the cost of treatment. As marketing protection expires for original, first-generation biopharmaceuticals, lower-cost ...
متن کاملThe Role of Biosimilars in Inflammatory Bowel Disease.
Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the most effective agents available. As the first of these biologic agents starts to come off patent, biosimilar agents have emerged as alternatives to originator drugs. The unique drug development and manufacturing processes in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gastroenterology & Hepatology: Open Access
سال: 2016
ISSN: 2373-6372
DOI: 10.15406/ghoa.2016.05.00131